Milestone Coincides with SK Biopharmaceuticals' Global Plan Expanding Cenobamate Access to More Than 100 Markets Worldwide

里程碑事件与SK Biopharmaceuticals的全球计划相吻合，该计划将Cenobamate扩展到全球100多个市场

GYEONGGI, Korea, and ROME, March 11, 2024 /PRNewswire/ -- SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CNS) disorders and oncology, and the first and only Korean company to independently develop and commercialize a new drug in the U.S., today announced more than 100,000 patients have been treated globally with cenobamate, an anti-seizure medication (ASM) developed by SK Biopharmaceuticals and its U.S.

韩国京畿道和罗马，2024年3月11日/PRNewswire/--SK Biopharmaceuticals Co.，Ltd.，一家专注于开发中枢神经系统疾病和肿瘤学治疗方法的全球生物技术公司，也是第一家也是唯一一家在美国独立开发和商业化新药的韩国公司，今天宣布，全球已有超过100000名患者接受了新诺胺治疗，SK Biopharmaceuticals及其美国公司开发的抗癫痫药物（ASM）。

subsidiary SK Life Science, Inc..

子公司SK生命科学公司。。

Cenobamate was first launched in the U.S. by SK Life Science, Inc. in 2020 after the Food and Drug Administration (FDA) approved the treatment for adults with partial-onset seizures. In the U.S., cenobamate is marketed under the brand name XCOPRI® (cenobamate tablets) CV. From 2021, with the approvals granted by the European Commission (EC) first, and subsequently by Swissmedic and MHRA, cenobamate was launched in Europe, Switzerland, and UK, under the brand name ONTOZRY® by SK Biopharmaceuticals' licensing partner Angelini Pharma SpA, part of the privately owned Angelini Industries, for the adjunctive treatment of focal-onset seizures in adult patients with epilepsy who have not been adequately controlled despite treatment with at least two antiseizure medications..

在美国食品和药物管理局（FDA）批准对部分发作性癫痫的成年人进行治疗后，SK Life Science，Inc.于2020年在美国首次推出了新诺胺。在美国，cenobamate以XCOPRI®（cenobamate片剂）CV.品牌销售。自2021年起，经欧盟委员会（EC）批准，随后由Swissmedic和MHRA批准，由SK Biopharmaceuticals的许可合作伙伴Angelini Pharma SpA以ONTOZRY®品牌在欧洲，瑞士和英国推出cenobamate，部分私营Angelini Industries，用于辅助治疗成年癫痫患者的局灶性癫痫发作，尽管使用了至少两种抗癫痫药物治疗，但仍未得到充分控制。。

Since 2023, Dexcel Pharma, an international specialty pharmaceutical company, has been marketing cenobamate in Israel, and Paladin Labs Inc., launched cenobamate in Canada. Both Dexcel and Paladin commercialized cenobamate under the XCOPRI brand name. Cenobamate is also being developed in over 30 markets by other licensing partners in Southeast Asia and Australia (Dong-A ST), 17 countries in Latin America (Eurofarma), the Middle East and North Africa (Hikma MENA FZE), the Greater China Area (Ignis Therapeutics), and Japan (Ono Pharmaceutical Co., Ltd.)..

自2023年以来，国际专业制药公司Dexcel Pharma一直在以色列销售cenobamate，Paladin Labs Inc.在加拿大推出cenobamate。Dexcel和Paladin都以XCOPRI品牌将cenobamate商业化。东南亚和澳大利亚（Dong-A ST）、拉丁美洲17个国家（Eurofarma）、中东和北非（Hikma MENA FZE）、大中华区（Ignis Therapeutics）和日本（Ono Pharmaceutical Co.，Ltd.）的其他许可合作伙伴也在30多个市场开发赛诺姆。。

'We are proud to see the impact that cenobamate is having on those patients living with epilepsy, a condition that is estimated to affect more than 50 million people globally,' said Donghoon Lee, President and CEO of SK Biopharmaceuticals and SK Life Science. 'This cenobamate milestone coincides with the completion earlier this year of SK Biopharmaceuticals' strategic Global Partnering plan.

SK Biopharmaceuticals和SK Life Science总裁兼首席执行官李东勋（Donghoon Lee）说，我们很自豪地看到新诺胺对癫痫患者的影响，据估计，这种情况会影响全球5000多万人这一cenobamate里程碑与SK Biopharmaceuticals今年早些时候完成的战略性全球合作计划相吻合。

The plan, resulting in cenobamate licensing agreements in Asia, Europe, North America, South America, and the Middle East and North Africa region (MENA), will potentially provide access to patients in more than 100 markets worldwide.'.

该计划在亚洲，欧洲，北美，南美以及中东和北非地区（MENA）达成了cenobamate许可协议，将有可能为全球100多个市场的患者提供服务。”。

'We are proud of our ongoing collaboration with SK Biopharmaceuticals and today's news reiterates the positive impact of our partnership in meeting the needs of people living with epilepsy in Europe,' said Jacopo Andreose, CEO of Angelini Pharma. 'We are excited to continue transforming the landscape of epilepsy care with innovative treatment options and to advocate for epilepsy as a priority for healthcare systems across Europe.'.

安吉利尼制药（Angelini Pharma）首席执行官雅各布·安德鲁斯（Jacopo Andreose）说：“我们为与SK生物制药（SK Biopharmaceuticals）的持续合作感到骄傲，今天的新闻重申了我们的合作伙伴关系在满足欧洲癫痫患者需求方面的积极影响。”我们很高兴能够继续通过创新的治疗方案改变癫痫治疗的格局，并倡导将癫痫作为欧洲医疗保健系统的优先事项。”。

About Epilepsy

关于癫痫

Epilepsy is the fourth most common neurological disorder. There are approximately 3.4 million people living with epilepsy in the United States, with 150,000 news cases each year in the country.1,2 Epilepsy is characterized by recurrent, unprovoked seizures. The seizures in epilepsy may be related to a brain injury or a family tendency, but often the cause is completely unknown.

癫痫是第四大最常见的神经系统疾病。美国大约有340万人患有癫痫病，该国每年有150000例新病例。1,2癫痫病的特征是反复发作，无缘无故发作。癫痫发作可能与脑损伤或家庭倾向有关，但通常原因完全未知。

Having seizures and epilepsy can affect one's safety, relationships, work, driving, and much more.3,4  People with epilepsy are at risk for accidents and other health complications, including falling, drowning, depression and sudden unexplained death in epilepsy (SUDEP).3,4 Despite the availability of many antiepileptic therapies, almost 40 percent of people with epilepsy are not able to achieve seizure freedom, meaning they have epilepsy that remains uncontrolled.5.

癫痫发作和癫痫会影响人的安全、人际关系、工作、驾驶等。3,4癫痫患者有发生事故和其他健康并发症的风险，包括跌倒、溺水、抑郁和癫痫猝死（SUDEP）。3,4尽管有许多抗癫痫药，几乎40%的癫痫患者无法实现癫痫发作自由，这意味着他们的癫痫病仍然无法控制。

About Cenobamate

关于Cenobamate

Cenobamate is an anti-seizure medication (ASM) discovered and developed by SK Biopharmaceuticals and SK Life Science, Inc. While the precise mechanism by which cenobamate exerts its therapeutic effect is unknown, it is believed to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents.

Cenobamate是SK Biopharmaceuticals和SK Life Science，Inc.发现和开发的一种抗癫痫药物（ASM）。虽然Cenobamate发挥其治疗效果的确切机制尚不清楚，但据信它可以通过抑制电压门控钠电流来减少重复性神经元放电。

It is also a positive allosteric modulator of the γ-aminobutyric acid (GABAA) ion channel. .

它也是γ-氨基丁酸（GABAA）离子通道的正变构调节剂。。

Cenobamate is approved in the United States for the treatment of partial-onset seizures in adults and is available under the brand name XCOPRI® (cenobamate tablets) CV. Cenobamate can be combined with other ASMs or used alone. The recommended initial dosage of cenobamate is 12.5 mg once-daily, with titration every two weeks; it is available in six tablet strengths for once-daily dosing: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg..

Cenobamate在美国被批准用于治疗 部分发作性癫痫 成年人和 以品牌XCOPRI®（cenobamate片剂）CV提供。 Cenobamate可以与其他ASM结合使用或单独使用。 氯硝胺的推荐初始剂量为12.5 mg，每天一次，每两周滴定一次；它有六种片剂强度，每天一次给药：12.5 mg、25 mg、50 mg、100 mg、150 mg和200 mg。。

Cenobamate is also approved in Canada where Paladin Labs Inc., an operating company of Endo International plc, launched cenobamate in January of 2024. Dexcel Pharma, an international specialty pharmaceutical company, is launching the treatment in Israel in April 2024. Both Dexcel and Paladin are marketing cenobamate under the brand name XCOPRI.

Cenobamate也在加拿大获得批准，Endo International plc的运营公司Paladin Labs Inc.于2024年1月推出了Cenobamate。国际专业制药公司Dexcel Pharma将于2024年4月在以色列推出该疗法。Dexcel和Paladin都在以XCOPRI品牌销售cenobamate。

.

.

Cenobamate is also approved in the European Union, in the United Kingdom and in Switzerland for the adjunctive treatment of focal-onset (partial-onset) seizures with or without secondary generalization in adult patients with seizures that have not been adequately controlled despite treatment with at least two anti-epileptic medicinal products and is marketed by Angelini Pharma under the brand name ONTOZRY®..

Cenobamate在欧盟、英国和瑞士也被批准用于局灶性发作（部分发作）的辅助治疗尽管使用了至少两种抗癫痫药进行了治疗，但成年癫痫发作患者的癫痫发作仍没有得到充分控制，并且由Angelini Pharma以ONTOZRY®品牌销售。。

Additionally, cenobamate is in clinical development in the Greater China region, Asia, Australia, Latin America, and the Middle East and North Africa via development and commercialization agreements with Ono Pharmaceutical, Ignis Therapeutics, Dong-A ST, Eurofarma, and Hikma MENA FZE.

此外，通过与Ono Pharmaceutical，Ignis Therapeutics，Dong-A ST，Eurofarma和Hikma MENA FZE的开发和商业化协议，cenobamate正在大中华地区，亚洲，澳大利亚，拉丁美洲以及中东和北非进行临床开发。

IMPORTANT SAFETY INFORMATION AND INDICATION FOR XCOPRI® (cenobamate tablets) CV

XCOPRI®（cenobamate片剂）CV的重要安全信息和适应症

DO NOT TAKE XCOPRI IF YOU:

如果您：

Are allergic to cenobamate or any of the other ingredients in XCOPRI.

对cenobamate或XCOPRI中的任何其他成分过敏。

Have a genetic problem (called Familial Short QT syndrome) that affects the electrical system of the heart.

患有影响心脏电系统的遗传问题（称为家族性短QT综合征）。

XCOPRI CAN CAUSE SERIOUS SIDE EFFECTS, INCLUDING:

XCOPRI会引起严重的副作用，包括：

Allergic reactions: XCOPRI can cause serious skin rash or other serious allergic reactions which may affect organs and other parts of your body like the liver or blood cells. You may or may not have a rash with these types of reactions. Call your healthcare provider right away and go to the nearest emergency room if you have any of the following: swelling of your face, eyes, lips, or tongue, trouble swallowing or breathing, a skin rash, hives, fever, swollen glands, or sore throat that does not go away or comes and goes, painful sores in the mouth or around your eyes, yellowing of your skin or eyes, unusual bruising or bleeding, severe fatigue or weakness, severe muscle pain, frequent infections, or infections that do not go away.

过敏反应：XCOPRI可引起严重皮疹或其他严重过敏反应，可能影响器官和身体其他部位，如肝脏或血细胞。你可能会也可能不会因为这些类型的反应而出现皮疹。如果您有以下任何一种情况，请立即致电您的医疗保健提供者，前往最近的急诊室：面部、眼睛、嘴唇或舌头肿胀，吞咽或呼吸困难，皮疹，荨麻疹，发烧，腺体肿胀或喉咙痛不会消失或消失，口腔或眼睛周围疼痛，皮肤或眼睛发黄，异常瘀伤或出血，严重的疲劳或虚弱，严重的肌肉疼痛，频繁的感染或不消失的感染。

Take XCOPRI exactly as your healthcare provider tells you to take it. It is very important to increase your dose of XCOPRI slowly, as instructed by your healthcare provider..

严格按照医疗保健提供者的指示服用XCOPRI。按照医疗保健提供者的指示，慢慢增加XCOPRI的剂量非常重要。。

QT shortening: XCOPRI may cause problems with the electrical system of the heart (QT shortening). Call your healthcare provider if you have symptoms of QT shortening including fast heartbeat (heart palpitations) that last a long time or fainting.

QT缩短：XCOPRI可能会导致心脏电气系统出现问题（QT缩短）。如果你有QT缩短的症状，包括持续很长时间的心跳加速（心悸）或昏厥，请致电你的医疗保健提供者。

Suicidal behavior and ideation: Antiepileptic drugs, including XCOPRI, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your health care provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes in behavior or mood..

自杀行为和意念：包括XCOPRI在内的抗癫痫药可能会在极少数人中引起自杀念头或行为，约占500人中的1人。如果你有以下任何症状，特别是如果它们是新的，更糟的，或者让你担心，请立即致电你的医疗保健提供者：关于自杀或死亡的想法；企图自杀；新的或更严重的抑郁，焦虑或烦躁；感到激动或不安；惊恐发作；睡眠困难（失眠）；表现出侵略性；愤怒或暴力；按危险的冲动行事；活动和谈话的极度增加（躁狂）；或其他不寻常的行为或情绪变化。。

Nervous system problems: XCOPRI may cause problems that affect your nervous system. Symptoms of nervous system problems include: dizziness, trouble walking or with coordination, feeling sleepy and tired, trouble concentrating, remembering, and thinking clearly, and vision problems. Do not drive, operate heavy machinery, or do other dangerous activities until you know how XCOPRI affects you..

神经系统问题：XCOPRI可能会导致影响神经系统的问题。神经系统问题的症状包括：头晕，行走或协调困难，感到困倦和疲倦，注意力不集中，记忆力和思维清晰，以及视力问题。在了解XCOPRI对您的影响之前，请勿驾驶、操作重型机械或进行其他危险活动。。

Do not drink alcohol or take other medicines that can make you sleepy or dizzy while taking XCOPRI without first talking to your healthcare provider.

在服用XCOPRI时，未事先与医疗保健提供者交谈，请勿饮酒或服用其他可能使您昏昏欲睡或头晕的药物。

DISCONTINUATION:

中止：

Do not stop taking XCOPRI without first talking to your healthcare provider. Stopping XCOPRI suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).

在没有先与您的医疗保健提供者交谈的情况下，不要停止服用XCOPRI。突然停止XCOPRI可能会导致严重问题。癫痫患者突然停止服用癫痫药物可能会导致癫痫发作无法停止（癫痫持续状态）。

DRUG INTERACTIONS:

药物相互作用：

XCOPRI may affect the way other medicines work, and other medicines may affect how XCOPRI works. Do not start or stop other medicines without talking to your healthcare provider. Tell healthcare providers about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements..

XCOPRI可能会影响其他药物的工作方式，其他药物可能会影响XCOPRI的工作方式。在没有与您的医疗保健提供者交谈的情况下，不要开始或停止其他药物。告诉医疗保健提供者你服用的所有药物，包括处方药和非处方药、维生素和草药补充剂。。

PREGNANCY AND LACTATION:

怀孕和哺乳期：

XCOPRI may cause your birth control medicine to be less effective. Talk to your health care provider about the best birth control method to use.

XCOPRI可能会导致你的避孕药物效果不佳。与你的医疗保健提供者谈谈最好的节育方法。

Talk to your health care provider if you are pregnant or plan to become pregnant. It is not known if XCOPRI will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking XCOPRI. You and your healthcare provider will decide if you should take XCOPRI while you are pregnant.

如果您怀孕或计划怀孕，请与您的医疗保健提供者联系。目前尚不清楚XCOPRI是否会伤害您的未出生婴儿。如果您在服用XCOPRI时怀孕，请立即告诉您的医疗保健提供者。您和您的医疗保健提供者将决定您是否应该在怀孕期间服用XCOPRI。

If you become pregnant while taking XCOPRI, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy. You can enroll in this registry by calling 1-888-233-2334 or go to www.aedpregnancyregistry.org..

如果您在服用XCOPRI时怀孕，请与您的医疗保健提供者联系，向北美抗癫痫药（NAAED）妊娠登记处注册。该登记处的目的是收集有关怀孕期间抗癫痫药安全性的信息。您可以通过拨打1-888-233-2334或访问www.aedpreginancyregistry.org注册此注册表。。

Talk to your health care provider if you are breastfeeding or plan to breastfeed. It is not known if XCOPRI passes into breastmilk. Talk to your healthcare provider about the best way to feed your baby while taking XCOPRI.

如果您正在母乳喂养或计划母乳喂养，请与您的医疗保健提供者联系。目前尚不清楚XCOPRI是否会进入母乳。与您的医疗保健提供者讨论服用XCOPRI时喂养宝宝的最佳方法。

COMMON SIDE EFFECTS:

常见副作用：

The most common side effects in patients taking XCOPRI include dizziness, sleepiness, headache, double vision, and feeling tired.

服用XCOPRI的患者最常见的副作用包括头晕、嗜睡、头痛、复视和疲倦。

These are not all the possible side effects of XCOPRI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch..

这些都不是XCOPRI可能产生的副作用。如果你有任何副作用困扰你或不会消失，请告诉你的医疗保健提供者。有关更多信息，请咨询您的医疗保健提供者或药剂师。打电话给你的医生，询问有关副作用的医疗建议。您可以通过1-800-FDA-1088或www.FDA.gov/medwatch向FDA报告副作用。。

DRUG ABUSE:

药物滥用：

XCOPRI is a federally controlled substance (CV) because it can be abused or lead to dependence. Keep XCOPRI in a safe place to prevent misuse and abuse. Selling or giving away XCOPRI may harm others and is against the law.

XCOPRI是一种联邦管制物质（CV），因为它可能被滥用或导致依赖。将XCOPRI保存在安全的地方，以防止滥用和滥用。出售或赠送XCOPRI可能会伤害他人，并且是违法的。

INDICATION:

适应症：

XCOPRI is a prescription medicine used to treat partial-onset seizures in adults 18 years of age and older. It is not known if XCOPRI is safe and effective in children under 18 years of age.

XCOPRI是一种处方药，用于治疗18岁及以上成年人的部分发作性癫痫发作。目前尚不清楚XCOPRI对18岁以下儿童是否安全有效。

Please see additional patient information in the Medication Guide. This information does not take the place of talking with your healthcare provider about your condition or your treatment.

请参阅药物指南中的其他患者信息。这些信息不能代替与您的医疗保健提供者谈论您的病情或治疗。

Please see full Prescribing Information.

请参阅完整的处方信息。

About SK Biopharmaceuticals Co., Ltd. and SK Life Science, Inc.

关于SK生物制药有限公司和SK生命科学有限公司。

SK Biopharmaceuticals and its U.S. subsidiary SK Life Science, Inc. are pharmaceutical companies focused on the research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals established a research center to begin their expansion into oncology.

SK Biopharmaceuticals及其美国子公司SK Life Science，Inc.是专注于中枢神经系统（CNS）和肿瘤学疾病治疗的研究，开发和商业化的制药公司。2017年，SK Biopharmaceuticals成立了一个研究中心，开始将其扩展到肿瘤学领域。

SK Biopharmaceuticals and SK Life Science, Inc. have a pipeline of eight compounds in development in both CNS disorders and oncology. Additionally, through SK Life Science Labs, its R&D subsidiary in the U.S., SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals' website at www.SKBP.com/eng, SK Life Science's website at www.SKLifeScienceInc.com, and SK Life Science Labs' website at www.SKLSLabs.com..

SK Biopharmaceuticals和SK Life Science，Inc.在中枢神经系统疾病和肿瘤学方面都有八种化合物正在开发中。此外，SK Biopharmaceuticals通过其在美国的研发子公司SK Life Science Labs专注于发现肿瘤学的新疗法。有关更多信息，请访问SK Biopharmaceuticals的网站www.SKBP.com/eng、SK Life Science的网站www.SKLifeScienceInc.com和SK Life Science Labs的网站www.SKLSLabs.com。。

SK Biopharmaceuticals, SK Life Science, and SK Life Science Labs are part of SK Group, one of the largest conglomerates in Korea. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors.

SK生物制药、SK生命科学和SK生命科学实验室是韩国最大的企业集团之一SK集团的一部分。SK公司是SK Biopharmaceuticals的母公司，通过与多个具有竞争力的子公司在各个业务领域进行长期投资，包括制药和生命科学、能源和化学品、信息和电信以及半导体，SK公司继续提高其投资组合价值。

In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses..

此外，SK Inc.专注于通过基于财务稳定的盈利和实用管理来加强其增长基础，同时通过投资未来新的增长业务来提高企业价值。。

About Angelini Pharma and Angelini Industries

关于Angelini Pharma和Angelini Industries

Angelini Pharma is an international pharmaceutical company, part of the Italian privately-owned multi-business Angelini Industries. The Company research, develops and commercialized health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health.

Angelini Pharma是一家国际制药公司，隶属于意大利私营多企业Angelini Industries。该公司研究、开发和商业化健康解决方案，重点关注大脑健康领域，包括心理健康和癫痫以及消费者健康。

Founded in Italy at the beginning of the 20th century, Angelini Pharma operates directly in 20 countries, employing more than 3,000 people. Its products are marketed in over 70 countries through strategic alliances with leading international pharmaceutical groups. For more information about Angelini Pharma please visit https://www.angelinipharma.com..

Angelini Pharma于20世纪初在意大利成立，直接在20个国家运营，员工超过3000人。其产品通过与国际领先制药集团的战略联盟在70多个国家销售。有关Angelini Pharma的更多信息，请访问https://www.angelinipharma.com..

Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over 2 billion euros, generated in the health, industrial technology, and consumer goods sectors.

Angelini Industries是由Francesco Angelini于1919年在安科纳成立的跨国工业集团。今天，Angelini Industries代表了一个坚实而多元化的工业现实，拥有约5800名员工，在全球21个国家运营，在健康、工业技术和消费品领域产生的收入超过20亿欧元。

A targeted investment strategy for growth; constant commitment to research and development; deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates. To learn more visit www.angeliniindustries.com..

有针对性的增长投资战略；不断致力于研究和开发；对市场和商业部门的深入了解，使Angelini Industries成为其运营部门中最优秀的意大利公司之一。欲了解更多信息，请访问www.angeliniindustries.com。。

XCOPRI® and ONTOZRY® are registered trademarks of SK Biopharmaceuticals Co., Ltd.

XCOPRI® 和安大略省® 是SK生物制药有限公司有限公司的注册商标。

This information is an estimate derived from the use of information under license from the following IQVIA information service: NPA, NSP, XPD for the period May 2020-December 2023. IQVIA expressly reserves all rights, including rights of copying, distribution, and republication.

该信息是根据以下IQVIA信息服务许可使用信息得出的估计值：2020年5月至2023年12月期间的NPA、NSP、XPD。IQVIA明确保留所有权利，包括复制、分发和再版的权利。

References

参考文献

Epilepsy Foundation. Who Can Get Epilepsy? https://www.epilepsy.com/learn/about-epilepsy-basics/who-gets-epilepsy. Accessed February 2024.

癫痫基金会。谁会患癫痫？https://www.epilepsy.com/learn/about-epilepsy-basics/who-gets-epilepsy.2024年2月访问。

Epilepsy Foundation. Facts & Statistics About Epilepsy. https://www.epilepsy.com/learn/about-epilepsy-basics/epilepsy-statistics. Accessed February 2024.

癫痫基金会。关于癫痫的事实和统计。https://www.epilepsy.com/learn/about-epilepsy-basics/epilepsy-statistics.2024年2月访问。

Epilepsy Foundation. Staying Safe. https://www.epilepsy.com/learn/seizure-first-aid-and-safety/staying-safe. Accessed February 2024.

癫痫基金会。保持安全。https://www.epilepsy.com/learn/seizure-first-aid-and-safety/staying-safe.2024年2月访问。

Epilepsy Foundation. Complications and Risks. https://www.epilepsy.com/learn/challenges-epilepsy. Accessed February 2024.

癫痫基金会。并发症和风险。https://www.epilepsy.com/learn/challenges-epilepsy.2024年2月访问。

Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. https://www.ncbi.nlm.nih.gov/pubmed/29279892. Published online December 26, 2017.

Chen Z，Brodie MJ，Liew D，Kwan P.用已建立和新的抗癫痫药治疗的新诊断癫痫患者的治疗结果：一项30年的纵向队列研究。https://www.ncbi.nlm.nih.gov/pubmed/29279892.2017年12月26日在线发布。

SOURCE SK Biopharmaceuticals Co., Ltd.

SOURCE SK生物制药有限公司。